{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T18:22:34Z","timestamp":1766514154050,"version":"build-2065373602"},"reference-count":25,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.autrev.2019.102439","type":"journal-article","created":{"date-parts":[[2019,11,14]],"date-time":"2019-11-14T13:10:52Z","timestamp":1573737052000},"page":"102439","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Systemic sclerosis induced by CNS stimulants for ADHD: A case series and review of the literature"],"prefix":"10.1016","volume":"19","author":[{"given":"Katya","family":"Meridor","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yair","family":"Levy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2019.102439_bb0005","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.autrev.2013.12.001","article-title":"Raynaud\u2019s phenomenon: from molecular pathogenesis to therapy","volume":"13","author":"Prete","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2019.102439_bb0010","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/nrrheum.2012.96","article-title":"The pathogenesis, diagnosis and treatment of Raynaud phenomenon","volume":"8","author":"Herrick","year":"2012","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.autrev.2019.102439_bb0015","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2014-006389","article-title":"Prevalence, risk factors and associations of primary Raynaud\u2019s phenomenon: systematic review and meta-analysis of observational studies","volume":"5","author":"Garner","year":"2015","journal-title":"BMJ Open"},{"key":"10.1016\/j.autrev.2019.102439_bb0020","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1177\/1358863X15579122","article-title":"Raynaud\u2019s phenomenon","volume":"20","author":"Ratchford","year":"2015","journal-title":"Vasc Med"},{"key":"10.1016\/j.autrev.2019.102439_bb0025","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/bcp.12912","article-title":"Drug-induced Raynaud\u2019s phenomenon: beyond \u03b2-adrenoceptor blockers","volume":"82","author":"Khouri","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.autrev.2019.102439_bb0030","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1097\/RHU.0b013e3181639aaa","article-title":"Methylphenidate and dextroamphetamine-induced peripheral vasculopathy","volume":"14","author":"Syed","year":"2008","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.autrev.2019.102439_bb0035","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1002\/art.23301","article-title":"Association between treatment with central nervous system stimulants and Raynaud\u2019s syndrome in children: a retrospective case-control study of rheumatology patients","volume":"58","author":"Goldman","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2019.102439_bb0040","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s11920-010-0093-y","article-title":"Peripheral vasculopathy associated with psychostimulant treatment in children with attention-deficit\/hyperactivity disorder","volume":"12","author":"Yu","year":"2010","journal-title":"Curr Psychiatry Rep"},{"key":"10.1016\/j.autrev.2019.102439_bb0045","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1089\/cap.2015.0033","article-title":"OROS-methylphenidate-induced Raynaud\u2019s phenomenon: a dose-related side effect","volume":"25","author":"Bayram","year":"2015","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.autrev.2019.102439_bb0050","first-page":"330","article-title":"Metilfenidato y fen\u00f3meno de Raynaud secundario","volume":"39","author":"Iglesias Otero","year":"2013","journal-title":"Semer - Med Fam"},{"key":"10.1016\/j.autrev.2019.102439_bb0055","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2310\/7750.2014.14052","article-title":"Diseases of abnormal sensitivity to cold in children on psychostimulant drugs","volume":"19","author":"Coulombe","year":"2015","journal-title":"J Cutan Med Surg"},{"key":"10.1016\/j.autrev.2019.102439_bb0060","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.autrev.2018.01.012","article-title":"Systemic lupus erythematosus and systemic sclerosis: all roads lead to platelets","volume":"17","author":"Scherlinger","year":"2018","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2019.102439_bb0065","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.autrev.2006.12.006","article-title":"Vascular complications of scleroderma","volume":"6","author":"Guiducci","year":"2007","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2019.102439_bb0070","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1136\/annrheumdis-2011-200742","article-title":"Update on the profile of the EUSTAR cohort: an analysis of the EULAR scleroderma trials and research group database","volume":"71","author":"Meier","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2019.102439_bb0075","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.autrev.2017.12.010","article-title":"Efficacy and safety of rituximab in systemic sclerosis: French retrospective study and literature review","volume":"17","author":"Thiebaut","year":"2018","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2019.102439_bb0080","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S0738-081X(98)00006-6","article-title":"Drug-induced scleroderma and sclerodermiform conditions","volume":"16","author":"Haustein","year":"1998","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.autrev.2019.102439_bb0085","first-page":"122","article-title":"Drug-induced localized systemic scleroses","volume":"92","author":"Graham","year":"1981","journal-title":"Trans Am Clin Climatol Assoc"},{"key":"10.1016\/j.autrev.2019.102439_bb0090","first-page":"573","article-title":"Drug induction in connective tissue diseases","volume":"149","author":"Verdelli","year":"2014","journal-title":"G Ital Dermatol Venereol"},{"key":"10.1016\/j.autrev.2019.102439_bb0095","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s00296-018-4227-6","article-title":"Systemic sclerosis induced by the use of cocaine: is there an association?","volume":"39","author":"Andreussi","year":"2019","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.autrev.2019.102439_bb0100","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1007\/s12016-017-8625-4","article-title":"Cutaneous manifestations of scleroderma and scleroderma-like disorders: a comprehensive review","volume":"53","author":"Ferreli","year":"2017","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.autrev.2019.102439_bb0105","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/jcpp.12381","article-title":"Annual research review: a meta-analysis of the worldwide prevalence of mental disorders in children and adolescents","volume":"56","author":"Polanczyk","year":"2015","journal-title":"J Child Psychol Psychiatry"},{"key":"10.1016\/j.autrev.2019.102439_bb0110","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1192\/bjp.bp.107.048827","article-title":"Prevalence and correlates of adult attention-deficit hyperactivity disorder: meta-analysis","volume":"194","author":"Simon","year":"2009","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.autrev.2019.102439_bb0115","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1007\/s00787-016-0820-y","article-title":"A 6-year follow-up of a large European cohort of children with attention-deficit\/hyperactivity disorder-combined subtype: outcomes in late adolescence and young adulthood","volume":"25","author":"van Lieshout","year":"2016","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"10.1016\/j.autrev.2019.102439_bb0120","doi-asserted-by":"crossref","first-page":"590","DOI":"10.2174\/1381612822666151124235816","article-title":"Psychopharmacology of attention-deficit hyperactivity disorder: effects and side effects","volume":"22","author":"Golmirzaei","year":"2016","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.autrev.2019.102439_bb0125","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1080\/14740338.2017.1301928","article-title":"An update on the safety of psychostimulants for the treatment of attention-deficit\/hyperactivity disorder","volume":"16","author":"Groenman","year":"2017","journal-title":"Expert Opin Drug Saf"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997219302502?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997219302502?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:16:07Z","timestamp":1761599767000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997219302502"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S1568997219302502"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2019.102439","relation":{},"ISSN":["1568-9972"],"issn-type":[{"type":"print","value":"1568-9972"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systemic sclerosis induced by CNS stimulants for ADHD: A case series and review of the literature","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2019.102439","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"102439"}}